Mark Cuban’s generic-drug play isn’t just another healthcare headline—it’s a stress test for the entire economics of “protected” medicine.
For years, the industry’s default story has been simple: innovation is expensive, patents create certainty, and e…

Biotech hiring is often treated like a lagging indicator—something that happens after the science is already funded, the pipeline is already de-risked, and the next clinical milestone is already “in motion.”
But in 2026, that assumption is getting risk…

Patent cliffs aren’t just a legal event. They’re a pricing strategy.
If you’ve worked anywhere near pharma—commercial, finance, strategy, or policy—you’ve seen the pattern: a blockbuster’s exclusivity ends, generic competition arrives, and revenue cu…

Drug pricing transparency is having a moment. In boardrooms and policy circles, the idea sounds almost surgical: publish the numbers, expose the math, and let sunlight do what regulation can’t. But the argument that “more transparency is always better”…

Mark Cuban’s Cost-Plus Drugs vs. Big Pharma: The Strategic War You Need to Be Modeling Right Now
The healthcare market is entering a phase that looks less like “policy debate” and more like competitive strategy—with winners and losers determined by pri…

Pharma doesn’t just “manage patents.” It manages time.
In the race for global exclusivity, the real asset isn’t only the molecule—it’s the calendar. And behind the scenes, companies are building systems to track IND and NDA milestones with near-obsessi…

Pharma doesn’t just “watch” patent dates. It engineers outcomes around them.
In the race to secure global exclusivity, the real advantage isn’t only having the best science—it’s having the best calendar. Drug Patent Watch’s latest piece on how companie…

Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you see what it does to patients, payers, and timelines.
Here’s the uncomfortable truth: Big Pharma can often delay generic entry without “losing in court.” …

Generics are no longer “copy-and-paste.” They’re a precision science—and the winners are learning to prove it.
For years, the generics playbook was simple: file, wait, and let the market do the rest. But as the bar for regulatory confidence rises—espec…

How does fruit juice impact Lipitor absorption? The effectiveness of Lipitor (atorvastatin), a statin medication used to… https://www.Drugchatter.com/chat/24737/does-lipitor’s-effectiveness-vary-with-any-fruit-juice/